DE602007012290D1 - Mischzell-populationen für die gewebereparatur und trenntechnik für die zellaufbereitung - Google Patents

Mischzell-populationen für die gewebereparatur und trenntechnik für die zellaufbereitung

Info

Publication number
DE602007012290D1
DE602007012290D1 DE602007012290T DE602007012290T DE602007012290D1 DE 602007012290 D1 DE602007012290 D1 DE 602007012290D1 DE 602007012290 T DE602007012290 T DE 602007012290T DE 602007012290 T DE602007012290 T DE 602007012290T DE 602007012290 D1 DE602007012290 D1 DE 602007012290D1
Authority
DE
Germany
Prior art keywords
biochamber
cells
enzyme
tissue repair
rinse solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012290T
Other languages
English (en)
Inventor
Brian Hampson
Kristin Goltry
Douglas M Smith
Jonathan A Rowley
Naia Venturi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vericel Corp
Original Assignee
Aastrom Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aastrom Biosciences Inc filed Critical Aastrom Biosciences Inc
Publication of DE602007012290D1 publication Critical patent/DE602007012290D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
DE602007012290T 2006-11-03 2007-11-05 Mischzell-populationen für die gewebereparatur und trenntechnik für die zellaufbereitung Active DE602007012290D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85650406P 2006-11-03 2006-11-03
US93270207P 2007-06-01 2007-06-01
PCT/US2007/023302 WO2008054825A2 (en) 2006-11-03 2007-11-05 Mixed cell populations for tissue repair and separation technique for cell processing

Publications (1)

Publication Number Publication Date
DE602007012290D1 true DE602007012290D1 (de) 2011-03-10

Family

ID=39344931

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012290T Active DE602007012290D1 (de) 2006-11-03 2007-11-05 Mischzell-populationen für die gewebereparatur und trenntechnik für die zellaufbereitung

Country Status (10)

Country Link
US (5) US7871605B2 (de)
EP (3) EP2086556B1 (de)
JP (4) JP5537153B2 (de)
AT (1) ATE496627T1 (de)
AU (1) AU2007314299B2 (de)
CA (2) CA2668330C (de)
DE (1) DE602007012290D1 (de)
DK (2) DK2086556T3 (de)
ES (2) ES2441560T3 (de)
WO (1) WO2008054825A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7699767B2 (en) 2002-07-31 2010-04-20 Arryx, Inc. Multiple laminar flow-based particle and cellular separation with laser steering
US11243494B2 (en) 2002-07-31 2022-02-08 Abs Global, Inc. Multiple laminar flow-based particle and cellular separation with laser steering
DE202007002538U1 (de) * 2007-02-21 2007-06-06 Krebs, Torsten Begasungsvorrichtung und -system
EP2581441A1 (de) * 2007-08-09 2013-04-17 Genzyme Corporation Verfahren zur Behandlung von Autoimmunerkrankungen mit mesenchymalen Stammzellen
WO2010019886A1 (en) * 2008-08-14 2010-02-18 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US20110223581A1 (en) * 2008-12-19 2011-09-15 Stobbe Tech A/S Electronically controlled diaphragm pump
US20110123455A1 (en) * 2009-11-12 2011-05-26 Presnell Sharon C Rational design of regenerative medicine products
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US20120100108A1 (en) * 2010-06-10 2012-04-26 Aastrom Biosciences, Inc. Compositions and methods of treating no-option critical limb ischemia (cli)
EP3679939A1 (de) * 2010-10-08 2020-07-15 Mesoblast International Sàrl Verbesserte msc-präparate
US10908066B2 (en) 2010-11-16 2021-02-02 1087 Systems, Inc. Use of vibrational spectroscopy for microfluidic liquid measurement
AU2012241521B2 (en) 2011-04-15 2016-07-14 Pluri Biotech Ltd Methods and systems for harvesting cells
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
CA2836102A1 (en) * 2011-05-18 2012-11-22 Aastrom Biosciences, Inc. Mesenchymal stromal cell populations and methods of making same
US9642897B2 (en) 2011-09-13 2017-05-09 The University Of Sydney Treatment of bone diseases
US20140099292A1 (en) * 2012-03-23 2014-04-10 Aastrom Biosciences, Inc. CD14+ Cell Compositions and Methods of Using Same
US20150086520A1 (en) * 2012-03-23 2015-03-26 Aastrom Biosciences, Inc. Cell Compositions and Methods of Using Same
US8927278B2 (en) * 2012-09-10 2015-01-06 National Health Research Institutes Method for generating immunomodulatory cells, the cells prepared therefrom, and use thereof
WO2014089397A1 (en) 2012-12-06 2014-06-12 Aastrom Biosciences, Inc. Compositions and methods of treating and preventing pulmonary fibrosis
US8859007B2 (en) * 2013-01-13 2014-10-14 Theracell, Inc. Oxygenated demineralized bone matrix for bone growth
US8961904B2 (en) 2013-07-16 2015-02-24 Premium Genetics (Uk) Ltd. Microfluidic chip
US20150037436A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11796449B2 (en) 2013-10-30 2023-10-24 Abs Global, Inc. Microfluidic system and method with focused energy apparatus
JP6437261B2 (ja) * 2014-09-26 2018-12-12 Ｐｈｃホールディングス株式会社 液体貯留ユニット及び分注システム
AU2016211688A1 (en) * 2015-01-26 2017-08-10 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP3259579B1 (de) 2015-02-19 2022-09-14 1087 Systems, Inc. Abtastendes infrarot-messsystem
EP3297694A1 (de) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modifizierte demineralisierte kortikale knochenfasern
AU2016296741A1 (en) 2015-07-21 2018-02-22 The Children's Medical Center Corporation PD-L1 expressing hematopoietic stem cells and uses
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
EP4151720A1 (de) * 2016-02-12 2023-03-22 Bluebird Bio, Inc. Vcn-förderer-zusammensetzungen und verfahren zur verwendung davon
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
WO2018076379A1 (zh) 2016-10-31 2018-05-03 华为技术有限公司 一种通话处理方法、终端及系统
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
WO2019226790A1 (en) 2018-05-23 2019-11-28 Abs Global, Inc. Systems and methods for particle focusing in microchannels
US20200054788A1 (en) * 2018-08-17 2020-02-20 Vivex Biomedical, Inc. Infused particles
EP3876953A4 (de) * 2018-12-11 2022-10-19 ERBI Biosystems, Inc. Verfahren zur herstellung von zellbasierten produkten unter verwendung von perfusionsprozessen mit kleinem volumen
EP4245140A3 (de) 2019-04-18 2024-01-17 ABS Global, Inc. System und verfahren zur kontinuierlichen zugabe eines kryoprotektivums
US11628439B2 (en) 2020-01-13 2023-04-18 Abs Global, Inc. Single-sheath microfluidic chip
CN114457014A (zh) * 2021-12-15 2022-05-10 南京医科大学 骨痂巨噬细胞分离用组合试剂及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839292B1 (en) 1987-09-11 1994-09-13 Joseph G Cremonese Cell culture flask utilizing membrane barrier
US5605822A (en) 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5763266A (en) 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5688687A (en) * 1995-06-07 1997-11-18 Aastrom Biosciences, Inc. Bioreactor for mammalian cell growth and maintenance
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US5985653A (en) 1995-06-07 1999-11-16 Aastrom Biosciences, Inc. Incubator apparatus for use in a system for maintaining and growing biological cells
US6096532A (en) 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
US6228635B1 (en) 1995-06-07 2001-05-08 Aastrom Bioscience, Inc. Portable cell growth cassette for use in maintaining and growing biological cells
EP2105138A3 (de) 1996-04-19 2013-06-05 Osiris Therapeutics, Inc. Regeneration und Augmentation von Knochen mit Hilfe von mesenchymalen Stammzellen
ATE307195T1 (de) 1997-07-14 2005-11-15 Osiris Therapeutics Inc Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
CA2302339A1 (en) 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
US20020034819A1 (en) 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
EP1062321B1 (de) 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DK1066052T3 (da) 1998-03-18 2006-06-12 Osiris Therapeutics Inc Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer
DE69910362T2 (de) 1998-04-03 2004-06-24 Osiris Therapeutics, Inc. Anwendung der mesenchymalen stammzellen als immunsuppressiva
ES2292245T3 (es) 1998-05-29 2008-03-01 Osiris Therapeutics, Inc. Celulas madre mesenquimaticas cd45+ y/o fibroblasto+humanas.
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US7097832B1 (en) 1999-03-30 2006-08-29 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
JP2004516242A (ja) 2000-07-26 2004-06-03 サイムド ライフ システムズ， インコーポレイテッド 心筋および骨格筋の虚血組織に骨髄由来の細胞移植をすることによる、治療を目的とした血管形成
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
CN1520312A (zh) * 2001-06-01 2004-08-11 �Ƹ��� T细胞诱导的组织修复和再生
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
ES2313805B1 (es) * 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
DE102004055615A1 (de) * 2004-11-16 2006-05-18 Universitätsklinikum Hamburg-Eppendorf In vitro aus Knochenmarkstammzellen differenzierte Retina-spezifische Zellen, ihre Herstellung und Verwendung
WO2006086716A2 (en) * 2005-02-10 2006-08-17 Xcyte Therapies, Inc. Donor lymphocyte infusion of activated t cells for the treatment of cancer

Also Published As

Publication number Publication date
US8158122B2 (en) 2012-04-17
DK2086556T3 (da) 2011-05-09
US20080175825A1 (en) 2008-07-24
EP2086556B1 (de) 2011-01-26
JP5767672B2 (ja) 2015-08-19
US20110124105A1 (en) 2011-05-26
CA2668330A1 (en) 2008-05-08
AU2007314299B2 (en) 2013-07-25
JP2015110652A (ja) 2015-06-18
JP6246754B2 (ja) 2017-12-13
EP2314300B1 (de) 2013-10-09
EP2314300A1 (de) 2011-04-27
CA2913024A1 (en) 2008-05-08
AU2007314299A1 (en) 2008-05-08
EP2465514A1 (de) 2012-06-20
WO2008054825A2 (en) 2008-05-08
WO2008054825A3 (en) 2008-11-20
CA2668330C (en) 2016-02-02
JP2017141298A (ja) 2017-08-17
WO2008054825A9 (en) 2008-07-03
JP5537153B2 (ja) 2014-07-02
US20160317584A1 (en) 2016-11-03
ES2362150T3 (es) 2011-06-29
EP2086556A2 (de) 2009-08-12
ATE496627T1 (de) 2011-02-15
US20110076294A1 (en) 2011-03-31
JP2013212115A (ja) 2013-10-17
US7871605B2 (en) 2011-01-18
US8394631B2 (en) 2013-03-12
DK2314300T3 (da) 2014-01-06
US9415071B2 (en) 2016-08-16
US20130209420A1 (en) 2013-08-15
ES2441560T3 (es) 2014-02-05
WO2008054825A8 (en) 2009-07-30
JP2010508818A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
DE602007012290D1 (de) Mischzell-populationen für die gewebereparatur und trenntechnik für die zellaufbereitung
RU2010103046A (ru) Культивирование отдельных плюрипотентных стволовых клеток
WO2007013899A3 (en) Continuous-batch hybrid process for production of oil and other useful products from photosynthetic microbes
MY143769A (en) An apparatus for mass cultivation of microalgae and a method for cultivating the same
EP2455111A3 (de) Zellcluster mit mehreren Zellarten aus dem Soma mit Fähigkeit zur Bildung primitiver organähnlicher Strukturen
EP1833961A4 (de) Verfahren zur kultivierung von geschmackszellen aus säugern
WO2008126667A3 (en) Method for producing lactic acid
AU2003261308A8 (en) Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
DK1543147T3 (da) Fremgangsmåde til påvisning af methicillinresistente Staphylococcus aureus
TW200716744A (en) Genetically modified microorganism and process for production of macrolide compound using the microorganism
WO2009007646A3 (fr) Systeme de production de microorganismes
WO2006119860A8 (de) Zellkultursystem sowie verfahren zur kultivierung einer zellkultur
WO2004033616A8 (de) Einrichtung zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
ATE469209T1 (de) Herstellung und verwendung von basalmembranpartikeln
WO2012032109A3 (de) Verfahren und vorrichtung zur herstellung von methan in einem photobioreaktor
CN101948745B (zh) 人工口腔模拟装置
CN105331576B (zh) 一种安水金线鲃脾脏细胞系的构建方法
WO2005054447A3 (en) Müller stem cells
CN101948746B (zh) 人工口腔模拟系统装置
Madireddi et al. Effect of carbon dioxide on the rheological behavior of submerged cultures of Chlorella minutissima in stirred tank reactors
WO2010038912A3 (ja) 微細藻類の培養方法及び装置
IL179318A (en) Methods for cultivating stem cells, cell cultures and the use of an egg for the cultivation of the stem cells
EP2399987A4 (de) Kulturmedium und verfahren zur induktion von differenzierung in knochenzellen
Rahmatnejad et al. A novel approach to noninvasive monitoring of dissolved carbon dioxide in small-scale cell culture processes
EP4119193A4 (de) Verfahren zur kultivierung von zellen aus epithelgewebe und zusammensetzung mit zellen, die durch dieses kultivierungsverfahren gezüchtet wurden